Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 10 Researches
7.5
USERS' SCORE
Good
Based on 4 Reviews
8.5
Supplement Facts
Serving Size: 1 Vegetable Capsule
Amount Per Serving
%DV
Iron (as iron bisglycinate chelate†)
25 mg
139%
Top Medical Research Studies
9
We investigated the role of iron treatment in managing heart disease, particularly its isolated effects. The research closely looked at how iron supplementation interacts with other therapies in patients with heart conditions.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
7
Ferric carboxymaltose efficacy in heart failure
In our investigation, we focused on a critical question: Can ferric carboxymaltose (FCM), an intravenous iron treatment, improve outcomes for patients with heart failure who have iron deficiency? To explore this, we conducted an extensive trial involving over 1100 patients diagnosed with chronic heart failure and reduced ejection fraction. These individuals were already battling iron deficiency, marked by low levels of serum ferritin and transferrin saturation.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
9
We explored the effectiveness of a bioconductive patch aimed at treating atrial fibrillation (AF) using superparamagnetic iron oxide nanoparticles. This patch not only improves electrical conduction but also helps reduce AF episodes in animal models. Over a 60-day period, the patch showed better outcomes than a standard gelatin variant, enabling continuous, noninvasive monitoring of its therapeutic effects through magnetic resonance imaging. However, further research is necessary to fully understand its long-term benefits in treating AF.
Most Useful Reviews
9
Significant relief
2 people found this helpful
After three days of taking this iron supplement, I felt a remarkable difference. For four years, I’ve struggled with a lack of oxygen, which traditional visits to cardiologists failed to address. Discovering this product provided such relief, like a weight was lifted from my lungs and heart! If you have similar symptoms, I recommend getting an iron test and considering this supplement, as it genuinely works.
9
Eased symptoms
1 people found this helpful
As a girl, I often experienced dizziness, fatigue, and abdominal pain during my menstrual periods. After consulting a doctor, I began iron supplementation, which is crucial for menstruating women. This iron supplement has no unpleasant smell. After taking it post-meal, my dizziness and headache vanished. Remember to limit coffee and strong tea, and increase vitamin C intake to enhance iron absorption!
8
Effective iron source
My wife has chronically low haemoglobin and requires consistent iron intake due to her condition. After trying numerous products, we've concluded that Solgar chelated iron is one of the few that truly helps her manage iron deficiency without causing gastrointestinal discomfort. I highly recommend these capsules over tablets for their gentler effect.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 10 Researches
7.5
- All Researches
9
We explored how iron impacts heart disease by developing a targeted delivery system that addresses myocardial ischemia-reperfusion injury (MIRI), a condition that leads to significant heart damage. This integrated system utilized cerium oxide (CeO) nanoparticles alongside dexrazoxane (DXZ), an iron-chelating agent, to improve therapeutic outcomes. By loading these components into mesoporous polydopamine nanoparticles, we aimed to enhance their delivery to the heart and specifically to the damaged mitochondria where they are most needed.
The results of our study were promising. We found that the combination of iron chelation and antioxidant properties significantly reduced oxidative stress and inhibited ferroptosis, a form of cell death linked to heart injury. Additionally, this approach led to improved cardiac function and reduced inflammation, which are crucial for recovery after MIRI.
Overall, this hierarchical targeting system offers a new avenue not only for the clinical use of DXZ but also for advancing nanomedicine interventions in heart repair. However, it’s important to note that while iron plays a role in this therapeutic approach, isolating its specific effects on heart disease remains challenging due to the combination with other treatment methods in our study.
The results of our study were promising. We found that the combination of iron chelation and antioxidant properties significantly reduced oxidative stress and inhibited ferroptosis, a form of cell death linked to heart injury. Additionally, this approach led to improved cardiac function and reduced inflammation, which are crucial for recovery after MIRI.
Overall, this hierarchical targeting system offers a new avenue not only for the clinical use of DXZ but also for advancing nanomedicine interventions in heart repair. However, it’s important to note that while iron plays a role in this therapeutic approach, isolating its specific effects on heart disease remains challenging due to the combination with other treatment methods in our study.
9
We investigated the role of iron treatment in managing heart disease, particularly its isolated effects. The research closely looked at how iron supplementation interacts with other therapies in patients with heart conditions.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
9
We investigated how Apelin-13 can protect heart cells from injury caused by lack of oxygen and subsequent reoxygenation, a significant issue in coronary artery disease. In our analysis, using heart cell models, we discovered that Apelin-13 reduces oxidative stress and improves heart cell function.
It lowers harmful iron levels and enhances protective substances in the cells, thus preventing cell death through a process called ferroptosis. Importantly, the protective effects depend on the activation of a specific protein called Nrf2. These findings suggest that Apelin-13 holds promise for future treatments in heart disease.
It lowers harmful iron levels and enhances protective substances in the cells, thus preventing cell death through a process called ferroptosis. Importantly, the protective effects depend on the activation of a specific protein called Nrf2. These findings suggest that Apelin-13 holds promise for future treatments in heart disease.
9
We explored the effectiveness of a bioconductive patch aimed at treating atrial fibrillation (AF) using superparamagnetic iron oxide nanoparticles. This patch not only improves electrical conduction but also helps reduce AF episodes in animal models. Over a 60-day period, the patch showed better outcomes than a standard gelatin variant, enabling continuous, noninvasive monitoring of its therapeutic effects through magnetic resonance imaging. However, further research is necessary to fully understand its long-term benefits in treating AF.
8
We explored how hemoglobin and serum iron levels relate to mortality risks in patients with coronary artery disease (CAD) by analyzing data from over 3,200 individuals.
Our findings showed that higher iron and hemoglobin levels were associated with a lower risk of dying from cardiovascular issues and overall. For instance, patients with the highest iron levels had a 51% reduced risk of cardiovascular death compared to those with the lowest levels.
While these findings are promising, we need more research to fully understand the impact of iron supplements on these patients' health.
Our findings showed that higher iron and hemoglobin levels were associated with a lower risk of dying from cardiovascular issues and overall. For instance, patients with the highest iron levels had a 51% reduced risk of cardiovascular death compared to those with the lowest levels.
While these findings are promising, we need more research to fully understand the impact of iron supplements on these patients' health.
User Reviews
USERS' SCORE
Good
Based on 4 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
9
Significant relief
2 people found this helpful
After three days of taking this iron supplement, I felt a remarkable difference. For four years, I’ve struggled with a lack of oxygen, which traditional visits to cardiologists failed to address. Discovering this product provided such relief, like a weight was lifted from my lungs and heart! If you have similar symptoms, I recommend getting an iron test and considering this supplement, as it genuinely works.
9
Eased symptoms
1 people found this helpful
As a girl, I often experienced dizziness, fatigue, and abdominal pain during my menstrual periods. After consulting a doctor, I began iron supplementation, which is crucial for menstruating women. This iron supplement has no unpleasant smell. After taking it post-meal, my dizziness and headache vanished. Remember to limit coffee and strong tea, and increase vitamin C intake to enhance iron absorption!
8
Effective iron source
My wife has chronically low haemoglobin and requires consistent iron intake due to her condition. After trying numerous products, we've concluded that Solgar chelated iron is one of the few that truly helps her manage iron deficiency without causing gastrointestinal discomfort. I highly recommend these capsules over tablets for their gentler effect.
7.5
Improved symptoms
I’ve been taking this type of iron for some time. The price and quality are reasonable. With severe iron deficiency leading to increased heart rate, I noticed symptoms subsided quickly after daily intake. However, it can cause constipation, so I take it responsibly.
Frequently Asked Questions
9
Significant relief
2 people found this helpful
After three days of taking this iron supplement, I felt a remarkable difference. For four years, I’ve struggled with a lack of oxygen, which traditional visits to cardiologists failed to address. Discovering this product provided such relief, like a weight was lifted from my lungs and heart! If you have similar symptoms, I recommend getting an iron test and considering this supplement, as it genuinely works.
9
Eased symptoms
1 people found this helpful
As a girl, I often experienced dizziness, fatigue, and abdominal pain during my menstrual periods. After consulting a doctor, I began iron supplementation, which is crucial for menstruating women. This iron supplement has no unpleasant smell. After taking it post-meal, my dizziness and headache vanished. Remember to limit coffee and strong tea, and increase vitamin C intake to enhance iron absorption!
8
Effective iron source
My wife has chronically low haemoglobin and requires consistent iron intake due to her condition. After trying numerous products, we've concluded that Solgar chelated iron is one of the few that truly helps her manage iron deficiency without causing gastrointestinal discomfort. I highly recommend these capsules over tablets for their gentler effect.
7.5
Improved symptoms
I’ve been taking this type of iron for some time. The price and quality are reasonable. With severe iron deficiency leading to increased heart rate, I noticed symptoms subsided quickly after daily intake. However, it can cause constipation, so I take it responsibly.
5
We explored the impact of intravenous iron treatment on patients with heart failure and iron deficiency through the HEART-FID trial. This large randomized, placebo-controlled study aimed to see if ferric carboxymaltose (FCM), given to patients, could improve health outcomes. Interestingly, while fewer patients treated with FCM died within 12 months compared to those receiving a placebo, the overall reduction in mortality was not statistically significant.
Our analysis highlighted that several factors were associated with all-cause mortality. Older age, diabetes, and higher levels of N-Terminal pro B-type natriuretic peptide (NT-proBNP) were linked to a greater risk of death. Additionally, we found that the effectiveness of FCM appeared to be greater in older women. This emphasizes the importance of personalizing treatment strategies based on individual patient characteristics.
While the results indicate a potentially meaningful reduction in deaths due to heart issues with iron treatment, the lack of statistical significance means we should be cautious in our interpretation. Patients and healthcare professionals may consider these findings when discussing treatment options for heart failure and iron deficiency moving forward.
Our analysis highlighted that several factors were associated with all-cause mortality. Older age, diabetes, and higher levels of N-Terminal pro B-type natriuretic peptide (NT-proBNP) were linked to a greater risk of death. Additionally, we found that the effectiveness of FCM appeared to be greater in older women. This emphasizes the importance of personalizing treatment strategies based on individual patient characteristics.
While the results indicate a potentially meaningful reduction in deaths due to heart issues with iron treatment, the lack of statistical significance means we should be cautious in our interpretation. Patients and healthcare professionals may consider these findings when discussing treatment options for heart failure and iron deficiency moving forward.
7
Iron levels impact heart function
We investigated how iron affects heart health in individuals with beta-thalassemia major (β-TM). In our study, we included 292 β-TM patients and 20 healthy individuals to compare their heart functions using cardiac magnetic resonance (CMR) technology.
Our findings revealed that iron overload in the heart is a significant concern for patients with β-TM. We found a strong correlation between high levels of myocardial iron overload (MIO) and lower heart function, evidenced by reduced left ventricular (LV) systolic indexes. This suggests that the more iron accumulated in the heart, the worse the heart's pumping ability tends to be.
While our analysis showed an association between iron levels and heart function, we did not find any significant improvement in heart function related to iron treatment itself in this population. Notably, the presence of late gadolinium enhancement (LGE), which indicates damage to the heart muscle, also appeared as a key factor affecting heart function in these patients.
Overall, while iron overload poses risks to heart health for β-TM patients, our study indicates that management of iron levels alone has not been proven to effectively improve heart function or prevent complications.
Our findings revealed that iron overload in the heart is a significant concern for patients with β-TM. We found a strong correlation between high levels of myocardial iron overload (MIO) and lower heart function, evidenced by reduced left ventricular (LV) systolic indexes. This suggests that the more iron accumulated in the heart, the worse the heart's pumping ability tends to be.
While our analysis showed an association between iron levels and heart function, we did not find any significant improvement in heart function related to iron treatment itself in this population. Notably, the presence of late gadolinium enhancement (LGE), which indicates damage to the heart muscle, also appeared as a key factor affecting heart function in these patients.
Overall, while iron overload poses risks to heart health for β-TM patients, our study indicates that management of iron levels alone has not been proven to effectively improve heart function or prevent complications.
7
Ferric carboxymaltose efficacy in heart failure
In our investigation, we focused on a critical question: Can ferric carboxymaltose (FCM), an intravenous iron treatment, improve outcomes for patients with heart failure who have iron deficiency? To explore this, we conducted an extensive trial involving over 1100 patients diagnosed with chronic heart failure and reduced ejection fraction. These individuals were already battling iron deficiency, marked by low levels of serum ferritin and transferrin saturation.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
9
We investigated the role of iron treatment in managing heart disease, particularly its isolated effects. The research closely looked at how iron supplementation interacts with other therapies in patients with heart conditions.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
References
- Margineanu C, Antohi L, Ambrosy A, Bartos D, Collins S, et al. Impact of iron deficiency on congestion and postdischarge survival in patients recently hospitalised for decompensated heart failure: a multicentre, prospective, observational analysis of the FERIC-RO study. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002851
- Zhu K, Wang K, Zhang R, Zhu Z, Wang W, et al. Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models. J Nanobiotechnology. 2025;23:112. doi:10.1186/s12951-025-03197-1
- Meloni A, Saba L, Positano V, Taccori M, Pistoia L, et al. Left ventricular diastolic and systolic functions by cardiac magnetic resonance in beta-thalassemia major: correlation with clinical findings and cardiac complications. Int J Cardiovasc Imaging. 2025. doi:10.1007/s10554-025-03352-7
- Ezekowitz JA, Mulder H, Mentz RJ, Butler J, DE Pasquale CG, et al. Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial. J Card Fail. 2025. doi:10.1016/j.cardfail.2025.01.009
- Anker SD, Friede T, Butler J, Talha KM, Diek M, et al. Rationale and design of the FAIR-HF2-DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure. Eur J Heart Fail. 2025. doi:10.1002/ejhf.3574
- Gan S, Azzo JD, Zhao L, Pourmussa B, Dib MJ, et al. Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations. Circ Heart Fail. 2025;18:e011728. doi:10.1161/CIRCHEARTFAILURE.124.011728
- Maeder MT, Verbrugge FH. Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure. Circ Heart Fail. 2025;18:e012675. doi:10.1161/CIRCHEARTFAILURE.124.012675
- Liang F, Li C, Liu Y, Sui Y. Apelin-13 Protects Against Myocardial Hypoxia/Reoxygenation (H/R) Injury by Inhibiting Ferroptosis Via Nrf2 Activation. J Biochem Mol Toxicol. 2025;39:e70223. doi:10.1002/jbt.70223
- Dychiao AT, Lu TH, Peng SY, Fan C, Song S, et al. Noninvasive assessment of a bioconductive patch for treating atrial fibrillation with magnetic resonance imaging. J Control Release. 2025;380:317. doi:10.1016/j.jconrel.2025.01.092
- Li Q, Pan Z, Zeng Y, Wang X, Li D, et al. Associations Between Hemoglobin and Serum Iron Levels and the Risk of Mortality Among Patients with Coronary Artery Disease. Nutrients. 2024;17. doi:10.3390/nu17010139
